Goldman Calls Medicis (MRX) 'One of the Most Likely M&A Targets' in Specialty Pharma Space
Tweet Send to a FriendGet Alerts MRX Hot Sheet
Price: $43.98 --0%
Rating Summary:
6 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
6 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade MRX Now!
Shares of Medicis Pharma (NYSE: MRX) are outperforming the broader equity market Friday morning following some promising comments from a Goldman Sachs' analyst earlier. While the stock is up about 1.8 percent at last check, the Dow and S&P 500 are down 17 points and up 1.8, respectively.
The firm said, "we believe the growth outlook remains underappreciated, with upside driven by Rx Assist initiatives (driving ASP improvement), new physician targeting strategies, and the launch of Zyclara. Further, we see MRX as one of the most likely M&A targets in the space, which should provide support amidst current market uncertainty."
Goldman maintains a Buy rating and $45 price target on shares of Medicis.
With the stock last trading around $37.10, the firm's price target implies potential upside of about 21 percent.
Track all the market-moving analyst calls on shares of Medicis with our Analyst Ratings page.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The firm said, "we believe the growth outlook remains underappreciated, with upside driven by Rx Assist initiatives (driving ASP improvement), new physician targeting strategies, and the launch of Zyclara. Further, we see MRX as one of the most likely M&A targets in the space, which should provide support amidst current market uncertainty."
Goldman maintains a Buy rating and $45 price target on shares of Medicis.
With the stock last trading around $37.10, the firm's price target implies potential upside of about 21 percent.
Track all the market-moving analyst calls on shares of Medicis with our Analyst Ratings page.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- Topeka Capital Starts Laredo Petroleum (LPI) at Buy, Assets 'Undervalued'
- Needham & Company Remains on Sidelines wth Applied Materials (AMAT) Post Q2
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Goldman Sachs, Standard & Poor's
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
